Trials / Terminated
TerminatedNCT03717012
Study of Pulmonary Rehabilitation in Patients With Idiopathic Pulmonary Fibrosis (IPF)
Study of Pulmonary Rehabilitation In Nintedanib Treated Patients With IPF: Improvements in Activity, Exercise Endurance Time, and QoL
- Status
- Terminated
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 19 (actual)
- Sponsor
- Boehringer Ingelheim · Industry
- Sex
- All
- Age
- 40 Years
- Healthy volunteers
- Not accepted
Summary
The main objectives of this study are: * Determine the difference in change from baseline in Six Minute Walk Distance (6MWD) when pulmonary rehabilitation (PR) is added to stable underlying nintedanib therapy in patients with idiopathic pulmonary fibrosis (IPF) * Determine the difference in change in Quality of Life (QoL) when pulmonary rehabilitation (PR) is added to stable underlying nintedanib therapy in patients with idiopathic pulmonary fibrosis (IPF) * Determine if there is an enduring effect in 6MWD, QoL and lung function from pulmonary rehabilitation (PR) when pulmonary rehabilitation (PR) is added to stable underlying nintedanib therapy in patients with idiopathic pulmonary fibrosis (IPF)
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Nintedanib | stable dose |
| OTHER | Pulmonary rehabilitation program | 12 weeks |
Timeline
- Start date
- 2018-11-15
- Primary completion
- 2020-03-27
- Completion
- 2020-06-10
- First posted
- 2018-10-23
- Last updated
- 2021-06-09
- Results posted
- 2021-06-09
Locations
19 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03717012. Inclusion in this directory is not an endorsement.